www.bloomberg.com
European stocks posted their fifth straight weekly gain, driven by investor optimism over sustained artificial intelligence demand. Novo Nordisk A/S surged 6.5%, leading market advances after UK regulators approved a higher-dose version of its popular obesity treatment.
Key highlights:
- Market Trend: The Stoxx 600 extended its winning streak to five weeks.
- Top Mover: Novo Nordisk rallied 6.5% following regulatory approval for a stronger dose of its weight-loss drug.
- Primary Driver: Sustained investor confidence in the growth potential of AI-related sectors.
